p51/p63, a novel p53 homologue, potentiates p53 activity and is a human cancer gene therapy candidate

Reiko Kunisaki, Shuntaro Ikawa, Toyoki Maeda, Yukoh Nakazaki, Ryo Kurita, Masamitsu Harata, Yukinobu Shutoh, Yuang Sung Bai, Yasushi Soda, Tsuyoshi Tanabe, Taeko Dohi, Rie Kato, Yoji Ikawa, Shigetaka Asano, Kenzaburo Tani

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: p51 (p73L/p63/p40/KET), a recently isolated novel p53 homologue, binds to p53-responsive elements to upregulate some p53 target genes and has been suggested to share partially overlapping functions with p53. p51 may be a promising candidate target molecule for anti-cancer therapy. Methods: In this study, we adenovirally transduced p51A cDNA into human lung, gastric and pancreatic cancer cells and analyzed the intracellular function of p51 in anti-oncogenesis in vitro and in vivo. Results: Overexpression of p51A revealed an anti-proliferative effect in vitro in all the cancer cells examined in this study. The anchorage-dependent and - independent cell growth of EBC1 cells carrying mutations in both p51 and p53 was suppressed and significant apoptosis following adenoviral transduction. with p51 and/or p53 was seen. This growth suppression was cooperatively enhanced by the combined infection with adenoviral vectors encoding both p51 and p53. Furthermore, p51 activated several, but not all, p53-inducible genes, indicating that the mechanisms controlling p51- and p53-mediated tumor suppression differed. Conclusions: Our observations indicate that, although p51 exhibited reduced anti-oncogenetic effects compared with p53, it cooperatively enhanced the anti-tumor effects of p53. Our results suggest that p51 functions as a tumor suppressor in human cancer cells in vitro and in vivo and may be useful as a potential tool for cancer gene therapy.

Original languageEnglish
Pages (from-to)1121-1130
Number of pages10
JournalJournal of Gene Medicine
Volume8
Issue number9
DOIs
Publication statusPublished - Sep 1 2006

Fingerprint

Neoplasm Genes
Genetic Therapy
Neoplasms
p53 Genes
Growth
Pancreatic Neoplasms
Stomach Neoplasms
Lung Neoplasms
Carcinogenesis
Up-Regulation
Complementary DNA
Apoptosis
Mutation
Infection
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Drug Discovery
  • Genetics(clinical)

Cite this

p51/p63, a novel p53 homologue, potentiates p53 activity and is a human cancer gene therapy candidate. / Kunisaki, Reiko; Ikawa, Shuntaro; Maeda, Toyoki; Nakazaki, Yukoh; Kurita, Ryo; Harata, Masamitsu; Shutoh, Yukinobu; Bai, Yuang Sung; Soda, Yasushi; Tanabe, Tsuyoshi; Dohi, Taeko; Kato, Rie; Ikawa, Yoji; Asano, Shigetaka; Tani, Kenzaburo.

In: Journal of Gene Medicine, Vol. 8, No. 9, 01.09.2006, p. 1121-1130.

Research output: Contribution to journalArticle

Kunisaki, R, Ikawa, S, Maeda, T, Nakazaki, Y, Kurita, R, Harata, M, Shutoh, Y, Bai, YS, Soda, Y, Tanabe, T, Dohi, T, Kato, R, Ikawa, Y, Asano, S & Tani, K 2006, 'p51/p63, a novel p53 homologue, potentiates p53 activity and is a human cancer gene therapy candidate', Journal of Gene Medicine, vol. 8, no. 9, pp. 1121-1130. https://doi.org/10.1002/jgm.945
Kunisaki, Reiko ; Ikawa, Shuntaro ; Maeda, Toyoki ; Nakazaki, Yukoh ; Kurita, Ryo ; Harata, Masamitsu ; Shutoh, Yukinobu ; Bai, Yuang Sung ; Soda, Yasushi ; Tanabe, Tsuyoshi ; Dohi, Taeko ; Kato, Rie ; Ikawa, Yoji ; Asano, Shigetaka ; Tani, Kenzaburo. / p51/p63, a novel p53 homologue, potentiates p53 activity and is a human cancer gene therapy candidate. In: Journal of Gene Medicine. 2006 ; Vol. 8, No. 9. pp. 1121-1130.
@article{d72c87dc3fea4120b33f72e27e76ce6d,
title = "p51/p63, a novel p53 homologue, potentiates p53 activity and is a human cancer gene therapy candidate",
abstract = "Background: p51 (p73L/p63/p40/KET), a recently isolated novel p53 homologue, binds to p53-responsive elements to upregulate some p53 target genes and has been suggested to share partially overlapping functions with p53. p51 may be a promising candidate target molecule for anti-cancer therapy. Methods: In this study, we adenovirally transduced p51A cDNA into human lung, gastric and pancreatic cancer cells and analyzed the intracellular function of p51 in anti-oncogenesis in vitro and in vivo. Results: Overexpression of p51A revealed an anti-proliferative effect in vitro in all the cancer cells examined in this study. The anchorage-dependent and - independent cell growth of EBC1 cells carrying mutations in both p51 and p53 was suppressed and significant apoptosis following adenoviral transduction. with p51 and/or p53 was seen. This growth suppression was cooperatively enhanced by the combined infection with adenoviral vectors encoding both p51 and p53. Furthermore, p51 activated several, but not all, p53-inducible genes, indicating that the mechanisms controlling p51- and p53-mediated tumor suppression differed. Conclusions: Our observations indicate that, although p51 exhibited reduced anti-oncogenetic effects compared with p53, it cooperatively enhanced the anti-tumor effects of p53. Our results suggest that p51 functions as a tumor suppressor in human cancer cells in vitro and in vivo and may be useful as a potential tool for cancer gene therapy.",
author = "Reiko Kunisaki and Shuntaro Ikawa and Toyoki Maeda and Yukoh Nakazaki and Ryo Kurita and Masamitsu Harata and Yukinobu Shutoh and Bai, {Yuang Sung} and Yasushi Soda and Tsuyoshi Tanabe and Taeko Dohi and Rie Kato and Yoji Ikawa and Shigetaka Asano and Kenzaburo Tani",
year = "2006",
month = "9",
day = "1",
doi = "10.1002/jgm.945",
language = "English",
volume = "8",
pages = "1121--1130",
journal = "Journal of Gene Medicine",
issn = "1099-498X",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - p51/p63, a novel p53 homologue, potentiates p53 activity and is a human cancer gene therapy candidate

AU - Kunisaki, Reiko

AU - Ikawa, Shuntaro

AU - Maeda, Toyoki

AU - Nakazaki, Yukoh

AU - Kurita, Ryo

AU - Harata, Masamitsu

AU - Shutoh, Yukinobu

AU - Bai, Yuang Sung

AU - Soda, Yasushi

AU - Tanabe, Tsuyoshi

AU - Dohi, Taeko

AU - Kato, Rie

AU - Ikawa, Yoji

AU - Asano, Shigetaka

AU - Tani, Kenzaburo

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Background: p51 (p73L/p63/p40/KET), a recently isolated novel p53 homologue, binds to p53-responsive elements to upregulate some p53 target genes and has been suggested to share partially overlapping functions with p53. p51 may be a promising candidate target molecule for anti-cancer therapy. Methods: In this study, we adenovirally transduced p51A cDNA into human lung, gastric and pancreatic cancer cells and analyzed the intracellular function of p51 in anti-oncogenesis in vitro and in vivo. Results: Overexpression of p51A revealed an anti-proliferative effect in vitro in all the cancer cells examined in this study. The anchorage-dependent and - independent cell growth of EBC1 cells carrying mutations in both p51 and p53 was suppressed and significant apoptosis following adenoviral transduction. with p51 and/or p53 was seen. This growth suppression was cooperatively enhanced by the combined infection with adenoviral vectors encoding both p51 and p53. Furthermore, p51 activated several, but not all, p53-inducible genes, indicating that the mechanisms controlling p51- and p53-mediated tumor suppression differed. Conclusions: Our observations indicate that, although p51 exhibited reduced anti-oncogenetic effects compared with p53, it cooperatively enhanced the anti-tumor effects of p53. Our results suggest that p51 functions as a tumor suppressor in human cancer cells in vitro and in vivo and may be useful as a potential tool for cancer gene therapy.

AB - Background: p51 (p73L/p63/p40/KET), a recently isolated novel p53 homologue, binds to p53-responsive elements to upregulate some p53 target genes and has been suggested to share partially overlapping functions with p53. p51 may be a promising candidate target molecule for anti-cancer therapy. Methods: In this study, we adenovirally transduced p51A cDNA into human lung, gastric and pancreatic cancer cells and analyzed the intracellular function of p51 in anti-oncogenesis in vitro and in vivo. Results: Overexpression of p51A revealed an anti-proliferative effect in vitro in all the cancer cells examined in this study. The anchorage-dependent and - independent cell growth of EBC1 cells carrying mutations in both p51 and p53 was suppressed and significant apoptosis following adenoviral transduction. with p51 and/or p53 was seen. This growth suppression was cooperatively enhanced by the combined infection with adenoviral vectors encoding both p51 and p53. Furthermore, p51 activated several, but not all, p53-inducible genes, indicating that the mechanisms controlling p51- and p53-mediated tumor suppression differed. Conclusions: Our observations indicate that, although p51 exhibited reduced anti-oncogenetic effects compared with p53, it cooperatively enhanced the anti-tumor effects of p53. Our results suggest that p51 functions as a tumor suppressor in human cancer cells in vitro and in vivo and may be useful as a potential tool for cancer gene therapy.

UR - http://www.scopus.com/inward/record.url?scp=33749248025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749248025&partnerID=8YFLogxK

U2 - 10.1002/jgm.945

DO - 10.1002/jgm.945

M3 - Article

C2 - 16832836

AN - SCOPUS:33749248025

VL - 8

SP - 1121

EP - 1130

JO - Journal of Gene Medicine

JF - Journal of Gene Medicine

SN - 1099-498X

IS - 9

ER -